Colossal Spinout Astromech Acquires Sister Company Form Bio for $230M

The all-stock deal brings together two Dallas companies, pairing Astromech’s evolutionary AI models with Form Bio’s tools for designing genetic medicines. Form Bio co-founder Andrew Busey becomes Astromech’s chief AI officer.

Ben Lamm

Two Austin startups that spun out of Dallas-based de-extinction behemoth Colossal Biosciences are coming together to tackle challenges in designing genetic medicine. 

Astromech, an AI company developing models to predict changes in living systems, said today it acquired Form Bio, a business that creates models and tools for designing genetic medicines. The acquisition is an all-stock deal valued at $230 million, the companies said. 

Form Bio co-founder and CEO Andrew Busey is now chief AI officer and head of technology at Astromech. The company said it also kept Form Bio’s AI, engineering and product teams. Astromech now employs 65 people.

“Form Bio began by solving the computational challenges discovered from de-extinction and has grown into a company building foundation models for the design of human therapeutics,” Busey, also co-founder of Colossal and Capital Factory, said in a statement announcing the acquisition.

“Our work with customers and partners has shaped that evolution, moving us from analyzing biological data to helping design genetic medicines,” he said. “Joining Astromech gives us the opportunity to build on that progress, bringing evolutionary insights into the design decisions we help researchers make.”

A decacorn’s journey

The deal is the latest evolution in tech entrepreneur Ben Lamm and Harvard geneticist George Church’s effort to reshape the way scientists think about issues like species extinction and genome engineering. The two co-founded Colossal Biosciences in 2021 and have grown the company into the first “decacorn” in Texas, with a value of more than $10 billion. 

Colossal Biosciences made a splash in 2025 with its announcement of the birth of three animals it calls dire wolves, a species that had been extinct for 12,500 years. It also is applying its combination of AI, CRISPR gene editing and conservation biology technology to bringing back the woolly mammoth, the Tasmanian tiger and the dodo bird.

As Colossal has grown, Lamm and Church have set up an ecosystem of businesses around its technology.

In addition to Form Bio and Astromech, Colossal Biosciences spun out a company called Breaking in 2024. Cambridge, Massachusetts-based Breaking is developing a microorganism called X-32 that breaks down plastics. That same year, it launched The Colossal Foundation to support conservation initiatives, including a “biovault” of genetic information for species close to extinction.

About Form Bio

Form Bio, which launched in September 2022, and has more than $40 million in venture financing of its own. Lamm co-founded it with Busey and serial entrepreneur Kent Wakeford, who is a Breaking co-founder.

Dallas-based Astromech acquired Form Bio in a $230 million all-stock deal, absorbing Form Bio’s intellectual property and team. [Image: Astromech]

Form Bio has been supporting genetic medicine programs at the pharmaceutical giant Eli Lilly, Stanford University and clinical-stage biotechnology companies. Its partners include Dallas-based Taysha Gene Therapies, Paris-based Coave Therapeutics and Charlestown, Massachusetts-based Solid Biosciences.

In its work with the Woodbridge, Connecticut-based nonprofit biotechnology company Cure Rare Disease on Duchenne muscular dystrophy, Form Bio increased full-genome content from 13% to 59% in less than 30 days by redesigning a promoter sequence. That program is now in preclinical studies in living organisms.

“Form Bio’s AI-driven design platform is helping us rapidly evaluate and prioritize gene therapy constructs across multiple programs,” Adrien Savy, director of discovery science at Coave, said in a statement.

Combined power

The Form Bio acquisition is a significant move for Astromech, which emerged from stealth mode in March. By August, Astromech had raised $60 million at a reported valuation of $3.8 billion. At the time, the company said it was using its recent capital infusion to expand its research team and infrastructure, and the number of species in its functional genomic datasets.

Form Bio is Astromech’s first acquisition. By bringing Form Bio’s tools for designing genetic medicines into the company, Astromech said it will be able to “help researchers move from identifying evolutionary patterns to designing and testing genetic constructs.” Form Bio expects to ultimately use the approach to produce therapies for humans and animals.

R E A D   N E X T